Authors
Ralph M Meyer, Mary K Gospodarowicz, Joseph M Connors, Robert G Pearcey, Andrea Bezjak, Woodrow A Wells, Bruce F Burns, Jane N Winter, Sandra J Horning, A Rashid Dar, Marina S Djurfeldt, Keyue Ding, Lois E Shepherd
Publication date
2005/7/20
Journal
Journal of Clinical Oncology
Volume
23
Issue
21
Pages
4634-4642
Publisher
American Society of Clinical Oncology
Description
Purpose
We report results of a randomized trial comparing ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy alone with treatment that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma.
Patients and Methods
Patients with nonbulky clinical stage I to IIA Hodgkin's lymphoma were stratified into favorable and unfavorable risk cohorts. Patients allocated to radiation-containing therapy received subtotal nodal radiation if favorable risk or combined-modality therapy if unfavorable risk. Patients allocated to ABVD received four to six treatment cycles.
Results
We evaluated 399 patients. Median follow-up is 4.2 years. In comparison with ABVD alone, 5-year freedom from disease progression is superior in patients allocated to radiation therapy (P = .006; 93% v 87%); no differences in event-free survival (P = .06; 88% v 86%) or …
Total citations
Scholar articles
RM Meyer, MK Gospodarowicz, JM Connors… - Journal of Clinical Oncology, 2005